This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): iduronate-2-sulfatase, IDS
Description: JR-032 is an enzyme replacement therapy of rDNA origin in development for Hunter Syndrome. It is manufactured using serum-free culture technology.
JR-032 was originally developed by JCR Pharmaceuticals.
In December 2009, GSK entered into an agreement with JCR Pharmaceuticals for the global rights to a number of enzyme replacement therapies to treat orphan diseases such as Hunter Syndrome, Fabry disease and Gaucher disease.
Partners: JCR Pharmaceuticals Co., Ltd.
Additional information available to subscribers only: